Table 1 Subject characteristics

Age, mean ± SD, in years

51.3 ± 12.6

BMI, mean ± SD, in kg/m²

23.2 ± 6.1

Chemotherapy, N (%)

 Antimetabolite (5-FU, capecitabine, gemcitabine, methotrexate)

41 (39.8)

 Anthracycline (doxorubicin, epirubicin)

40 (38.8)

 Alkylating agents (cyclophosphamide)

34 (33)

 Taxane (docetaxel, paclitaxel)

36 (34.9)

 Platinum (carboplatin, cisplatin)

23 (22.3)

 Vinca alkaloid (vinorelbine)

2 (1.9)

 Antimicrotubule (eribulin)

2 (1.9)

Histopathology, N (%)

 NST

95 (92.2)

 Lobular

3 (2.9)

 Others (metaplastic, papillary, medullary)

5 (4.9)

Histo grade, N (%)

 I

1 (1)

 II

33 (32)

 III

56 (54.4)

 N/A

13 (12.6)

Ki-67, N (%)

  < 20%

10 (9.7)

  ≥ 20%

89 (86.4)

  N/A

4 (3.9)

Site of metastasis, N (%)

 Bone

51 (49.5)

 Lung

58 (56.3)

 Liver

30 (29.1)

 Brain

11 (10.7)

 Others (adrenal, soft tissue)

2 (1.9)